Pfizer CEO Albert Bourla said Tuesday the company will be able to provide the U.S. 10% more vaccine doses than it originally agreed to by the end of May, a move that will boost vaccine supply after regulators recommended a pause on administering Johnson & Johnson’s vaccine.
In addition to ramping up production in May, Bourla said in a tweet the company can deliver a total of 300 million doses two weeks earlier than anticipated before the end of July.
The announcement comes after the CDC and FDA recommended a temporary halt to Johnson & Johnson’s vaccine Tuesday over extremely rare blood clots from the shot—through the Biden administration has said the pause won’t significantly impact its overall vaccine plan because the Johnson & Johnson vaccine only makes up less than 5% of the recorded shots in the U.S. to date.
Several counties and states have already committed to giving patients the Pfizer vaccine in place of Johnson & Johnson during the pause.
The U.S. so far has vaccinated 20% of the population, while President Joe Biden expects to have enough vaccines available for every American by the end of May. Biden plans for Americans to be able to gather with friends and family for the Fourth of July, though case rates in some states, such as Michigan, New York, Florida, Pennsylvania and New Jersey, are on the rise again despite vaccinations.